在烧伤重症监护病房暴发期间，对头孢地尔耐药鲍曼不动杆菌的进化和传播。
Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.
机构信息
Department of Pharmacy, Cooperman Barnabas Medical Center, Livingston, New Jersey, USA.
Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
出版信息
Clin Infect Dis. 2023 Feb 8;76(3):e1261-e1265. doi: 10.1093/cid/ciac647.
Abstract
We report on 11 critically ill burn patients treated with cefiderocol for carbapenem-resistant Acinetobacter baumannii infections. Clinical success was achieved in 36% and complicated by treatment-emergent resistance and interpatient transmission of cefiderocol-resistant A. baumannii. Resistant isolates harbored disrupted pirA and piuA genes that were not disrupted among susceptible isolates.
摘要
我们报告了 11 例重症烧伤患者使用头孢地尔治疗碳青霉烯类耐药鲍曼不动杆菌感染的情况。临床治愈率为 36%，但治疗中出现了耐药性和耐头孢地尔的鲍曼不动杆菌在患者间的传播。耐药分离株携带的 pirA 和 piuA 基因被破坏，而敏感分离株则没有被破坏。
相似文献
1
Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.
Clin Infect Dis. 2023 Feb 8;76(3):e1261-e1265. doi: 10.1093/cid/ciac647.
2
Evolution, control and success of combination therapy with Ampicilin-sulbactam/Ceftazidime-Avibactam during a Carbapenem-Resistant Acinetobacter baumannii outbreak in burn Intensive Care Unit.
Eur J Clin Microbiol Infect Dis. 2024 Jul;43(7):1453-1459. doi: 10.1007/s10096-024-04840-9. Epub 2024 Apr 27.
3
Treatment-emergent cefiderocol resistance in carbapenem-resistant is associated with insertion sequence IS in the siderophore receptor .
Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0029024. doi: 10.1128/aac.00290-24. Epub 2024 May 29.
4
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15.
5
Accumulation of Antibiotic Resistance Genes in Carbapenem-Resistant Isolates Belonging to Lineage 2, Global Clone 1, from Outbreaks in 2012-2013 at a Tehran Burns Hospital.
mSphere. 2020 Apr 8;5(2):e00164-20. doi: 10.1128/mSphere.00164-20.
6
Adaptations of carbapenem resistant (CRAB) in the hospital environment causing sustained outbreak.
J Med Microbiol. 2021 Mar;70(3). doi: 10.1099/jmm.0.001345. Epub 2021 Mar 19.
7
First detection of a cefiderocol-resistant and extensively drug-resistant Acinetobacter baumannii clinical isolate in Bulgaria.
Acta Microbiol Immunol Hung. 2024 Jan 23;71(1):25-36. doi: 10.1556/030.2024.02201. Print 2024 Mar 26.
8
Molecular characterization and antimicrobial susceptibility of Acinetobacter baumannii isolates obtained from two hospital outbreaks in Los Angeles County, California, USA.
BMC Infect Dis. 2016 May 4;16:194. doi: 10.1186/s12879-016-1526-y.
9
Nosocomial Outbreak of Extensively Drug-Resistant Acinetobacter baumannii Isolates Containing Carried on a Plasmid.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00797-17. Print 2017 Nov.
10
Hetero-antagonism of avibactam and sulbactam with cefiderocol in carbapenem-resistant spp.
Microbiol Spectr. 2024 Oct 3;12(10):e0093024. doi: 10.1128/spectrum.00930-24. Epub 2024 Aug 20.
引用本文的文献
1
Evaluating Antimicrobial Susceptibility Testing Methods for Cefiderocol: A Review and Expert Opinion on Current Practices and Future Directions.
Antibiotics (Basel). 2025 Jul 28;14(8):760. doi: 10.3390/antibiotics14080760.
2
treatment strategies: a review of therapeutic challenges and considerations.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
3
Comparative activity of sulbactam with avibactam or durlobactam against carbapenem-resistant .
JAC Antimicrob Resist. 2025 Jun 23;7(3):dlaf098. doi: 10.1093/jacamr/dlaf098. eCollection 2025 Jun.
4
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections.
Drugs. 2025 Jan;85(1):21-40. doi: 10.1007/s40265-024-02104-6. Epub 2024 Nov 28.
5
Heterogeneity and Genomic Plasticity of Acinetobacter baumannii and Acinetobacter nosocomialis Isolates Recovered from Clinical Samples in India.
Curr Microbiol. 2024 Oct 19;81(12):415. doi: 10.1007/s00284-024-03942-z.
6
Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii.
NPJ Biofilms Microbiomes. 2024 Sep 30;10(1):92. doi: 10.1038/s41522-024-00560-2.
7
Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant infections.
JAC Antimicrob Resist. 2024 Sep 9;6(5):dlae146. doi: 10.1093/jacamr/dlae146. eCollection 2024 Oct.
8
Challenges Facing Two Outbreaks of Carbapenem-Resistant : From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants.
Antibiotics (Basel). 2024 Aug 21;13(8):784. doi: 10.3390/antibiotics13080784.
9
transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti- drug development and AMR preparedness.
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0022224. doi: 10.1128/aac.00222-24. Epub 2024 Aug 27.
10
Unveiling the Secrets of : Resistance, Current Treatments, and Future Innovations.
Int J Mol Sci. 2024 Jun 21;25(13):6814. doi: 10.3390/ijms25136814.
本文引用的文献
1
Carbapenem-Resistant Acinetobacter baumannii in U.S. Hospitals: Diversification of Circulating Lineages and Antimicrobial Resistance.
mBio. 2022 Apr 26;13(2):e0275921. doi: 10.1128/mbio.02759-21. Epub 2022 Mar 21.
2
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.
Clin Infect Dis. 2022 Jul 6;74(12):2089-2114. doi: 10.1093/cid/ciab1013.
3
Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists.
Infect Dis Ther. 2021 Dec;10(4):2177-2202. doi: 10.1007/s40121-021-00541-4. Epub 2021 Oct 14.
4
Increase in Hospital-Acquired Carbapenem-Resistant Acinetobacter baumannii Infection and Colonization in an Acute Care Hospital During a Surge in COVID-19 Admissions - New Jersey, February-July 2020.
MMWR Morb Mortal Wkly Rep. 2020 Dec 4;69(48):1827-1831. doi: 10.15585/mmwr.mm6948e1.
5
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
6
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024. doi: 10.1093/cid/ciaa1410.
7
Microbiome in the setting of burn patients: implications for infections and clinical outcomes.
Burns Trauma. 2020 Aug 14;8:tkaa033. doi: 10.1093/burnst/tkaa033. eCollection 2020.
8
CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database.
Nucleic Acids Res. 2020 Jan 8;48(D1):D517-D525. doi: 10.1093/nar/gkz935.
9
Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications.
Wellcome Open Res. 2018 Sep 24;3:124. doi: 10.12688/wellcomeopenres.14826.1. eCollection 2018.
10
Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.
Zotero 插件